Category: Content Updates

AHFS Patient Medication Information Update – March 2017

17 March, 2017 no responses

The March update to the AHFS Patient Medication Information (PMI) database has been published. Highlights of the update include:

New PMI Monographs

  • Hydrocortisone Rectal (Anusol HC®, Colocort®, Cortenema®, Preparation H Anti-Itch®, Proctocort®, Proctofoam HC®)
    • Rectal hydrocortisone is used along with other medications to treat proctitis (swelling in the rectum) and ulcerative colitis (a condition which causes swelling and sores in the lining of the large intestine and rectum).
  • Lixisenatide Injection (Adlyxin®)
    • Lixisenatide injection is used along with diet and exercise to treat type 2 diabetes.
  • Cromolyn Ophthalmic (Crolom®)
    • Cromolyn ophthalmic is used to treat the symptoms of allergic conjunctivitis (a condition in which the eyes become itchy, swollen, red, and teary when they are exposed to certain substances) and keratitis (a condition that causes swelling of the cornea [tissue in the front of the eye] that causes eye redness, pain, and tearing and changes in vision).
  • Bezlotoxumab Injection (Zinplava®)
    • Bezlotoxumab injection is used to decrease the risk of Clostridium difficile infection (a type of bacteria that can cause severe or life-threatening diarrhea) from coming back in people at high risk for C. difficile infection.

FDA MedWatch Alert Revisions

FDA is warning that eluxadoline (Viberzi®), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder.

AHFS Drug Information/Essentials Update – January 2017

12 January, 2017 no responses

The January update to the AHFS Drug Information/Essentials database has been published. Highlights from this month’s update include:

New AHFS/Essentials Monographs

  • New Full-Length Monographs
    • Netupitant And Palonosetron (Akynzeo®)
      • Netupitant and palonosetron hydrochloride are used orally in fixed combination for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
    • Sugammadex (Bridion®)
      • Sugammadex is used for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in patients undergoing surgery.
  • New First-Release Monographs
    • Rucaparib (Rubraca®)
      • Rucaparib camsylate is a PARP inhibitor indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies.
    • Nusinersen (Spinraza®)
      • Nusinersen sodium is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

FDA MedWatch Alerts

  • FDA is warning that repeated or lengthy use of general anesthetic and sedation drugs during surgeries or procedures in children younger than 3 years or in pregnant women during their third trimester may affect the development of children’s brains.
    • Affected Monographs:
      • Propofol
      • Etomidate
      • Lorazepam
      • Pentobarbital
      • Midazolam
      • Methohexital
  • As a result of an updated review, the FDA has concluded that use of the type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer.
    • Affected Monographs:
      • Pioglitazone
  • FDA determined the risk of serious side effects on mood, behavior, or thinking with the stop-smoking medicines varenicline (Chantix®) and bupropion (Zyban®) is lower than previously suspected.
    • Affected Monographs:
      • Varenicline
      • Bupropion

AHFS Drug Information/Essentials Update – December 2016

12 December, 2016 no responses

The December update to the AHFS Drug Information/Essentials database has been published. Highlights from this month’s update include:

New AHFS/Essentials Monographs

  • Sacubitril/valsartan (Entresto with Valsartan®)
  • Cariprazine (Vraylar®)
  • Idarucizumab (Praxbind®)
  • Brivaracetam (Briviact®)
  • Pimavanserin Tartrate (Nuplazid®)
  • Tenofovir Alafenamide Fumarate (Vemlidy®)

FDA MedWatch Alerts

  • No new MedWatch Alerts
1 … 4 5 6 7 8 … 11
© 2022, American Society of Health-System Pharmacists®. All rights reserved.